Test of fostamatinib with chemo before and after surgery for pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests adding a new drug, fostamatinib, to standard chemotherapy before and after surgery for pancreatic cancer that can be removed. The goal is to see if the combination helps reduce the chance of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is in the pancreas and can be removed with surgery (based on a recent CT or MRI scan).
- You have not had any treatment for pancreatic cancer before.
- You are in generally good health, able to do normal daily activities, and have no major infections.
- You have adequate liver, kidney, and blood cell counts (your doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called pumitamig combined with standard chemotherapy for people with advanced pancreatic cancer that has spread and has not been treated yet. The goal is to see if this combination is safe and effective.
This trial tests a new combination of three drugs for a type of pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body. The goal is to see if this combination can shrink or slow the cancer better than the current standard therapy.
This trial tests a new drug called nuzefatide pevedotin for people with metastatic pancreatic cancer that has progressed after one prior treatment. The drug targets a protein called EphA2 found on some tumor cells and may slow tumor growth.
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
This trial tests a new chemotherapy combination after surgery for pancreatic cancer to see if it helps prevent the cancer from coming back. It compares the new treatment to a standard one.
This trial tests a new combination of two targeted therapy drugs (avutometinib and defactinib) plus standard chemotherapy (mFOLFIRINOX) given before any other treatment for pancreatic cancer. The goal is to see if this combination can shrink tumors more effectively and improve outcomes for patients with advanced pancreatic cancer.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.